奥拉帕利维持治疗在韩国BRCA突变卵巢癌患者中的真实世界疗效与毒性及BRCA突变探索性分析
该回顾性分析纳入韩国BRCA突变卵巢癌患者,评估奥拉帕利维持治疗的真实世界疗效与毒性。一线维持组2年无进展生存率为75.5%,二线及以上维持组为54.8%。p.Leu1780Pro BRCA1突变是一线维持无进展生存的不良预后因素(HR 5.66)。
要点
- 一线维持治疗组2年无进展生存率75.5%,3年总生存率98.5%。
- 二线及以上维持治疗组2年无进展生存率54.8%,3年总生存率87.3%。
- p.Leu1780Pro BRCA1突变是一线维持无进展生存的不良预后因素(HR 5.66)。
核心结论
- 奥拉帕利维持治疗在韩国BRCA突变卵巢癌患者中有效且可耐受,但p.Leu1780Pro BRCA1突变在一线维持中的不良预后需进一步研究。
研究设计与样本
- 回顾性分析韩国Asan Medical Center于2015年8月至2023年4月接受奥拉帕利维持治疗的BRCA突变卵巢癌患者,一线维持组70例,二线及以上维持组83例。
主要发现
- 一线维持组(n=70)2年无进展生存率为75.5%,3年总生存率为98.5%。
- 二线及以上维持组(n=83)2年无进展生存率为54.8%,3年总生存率为87.3%。
- p.Leu1780Pro BRCA1突变是一线维持无进展生存的不良预后因素(风险比[HR] 5.66)。
- 二线及以上维持组中,无铂间期≥12个月与更好的无进展生存(校正HR 0.48)和总生存(校正HR 0.31)相关。
- 二线及以上维持组中,奥拉帕利起始时CA-125≥10 IU/mL是不良预后因素(校正HR 2.12)。
关键数值与推荐
- 一线维持组中,末次化疗与维持治疗之间较长时间间隔与维持治疗期间≥3级血液学毒性减少相关(比值比0.75)。
- 因毒性停药在一线维持组占1.4%,在二线及以上维持组占6.0%。
临床怎么用
- 原文未据此给出推荐。
局限性
- p.Leu1780Pro BRCA1突变在一线维持中的不良预后需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the real-world efficacy and toxicity of olaparib maintenance therapy in Korean patients with BRCA-mutated ovarian cancer (OC), with an exploratory analysis of BRCA mutations. METHODS: We conducted a retrospective analysis of Korean BRCA-mutated OC patients treated with olaparib maintenance therapy as first-line (1Lm) or second-/subsequent-line (2Lm +) at Asan Medical Center, South Korea, from August 2015 to April 2023. Survival outcomes, including progression-free survival (PFS) and overall survival (OS), as well as toxicity, were analyzed with patient characteristics and BRCA mutations. RESULTS: In 1Lm (n = 70), the 2-year PFS was 75.5 % and the 3-year OS was 98.5 %. In 2Lm + (n = 83), the 2-year PFS was 54.8 % and the 3-year OS was 87.3 %. The pathogenic p.Leu1780Pro BRCA1 mutation was a poor prognostic factor for PFS in 1Lm (hazard ratio [HR], 5.66). In 2Lm +, platinum-free interval ≥ 12 months was associated with better PFS (adjusted HR [aHR], 0.48) and OS (aHR, 0.31), whereas CA-125 ≥ 10 IU/mL at olaparib initiation was a poor prognostic factor (aHR, 2.12). A longer time interval between the last chemotherapy and maintenance therapy in 1Lm correlated with reduced hematologic toxicity ≥ grade 3 (odd ratio, 0.75) during maintenance therapy. Drug discontinuation due to toxicity occurred in 1.4 % of 1Lm and 6.0 % of 2Lm + . CONCLUSIONS: Olaparib maintenance therapy was effective and tolerable in Korean BRCA-mutated OC patients, though the poor prognosis of the p.Leu1780Pro BRCA1 mutation in 1Lm warrants further investigation.
引用
- Kim J, Park SY, Kim JH, et al. Real-world efficacy and toxicity of olaparib maintenance therapy in Korean ovarian cancer patients with an exploratory analysis of BRCA mutations. Gynecol Oncol. 2025. PMID: 39923681. doi:10.1016/j.ygyno.2025.01.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。